TARDBP and amyotrophic lateral sclerosis: To overcome these limitations, we implemented transient proteasome inhibition as a highly reproducible, dose-responsive, temporally controlled model to induce TDP-43 nuclear loss as seen in patients’ Betz cells and other ALS-related dysfunction in human neurons4,37,38 (Fig. 4a and Extended Data Fig. 6a,b).